Clinical Prognostic Score to Predict Relapse in VL

Launched by INSTITUTE OF TROPICAL MEDICINE, BELGIUM · Oct 27, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on developing a tool to help predict whether patients with visceral leishmaniasis (VL), a serious disease often found in certain regions of Ethiopia, might experience a relapse after treatment. The researchers will carefully observe and collect information from patients who are confirmed to have VL, looking at various factors that could influence their recovery. The goal is to improve patient care, reduce serious complications, and ensure better follow-up for those at risk of relapse.

To be eligible for this study, participants must be 12 years or older and have a confirmed diagnosis of VL. However, individuals who have already been on treatment for more than three days, are in a severe medical condition, are pregnant or breastfeeding, or have difficulty attending follow-up visits cannot participate. If you join the study, you can expect to be monitored closely throughout your treatment to help gather important information that could benefit future patients with VL.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • clinically or parasitologically confirmed VL
• Exclusion Criteria:
• • Age under 12 years
• • VL patients already on treatment for 3 days or more
• • Severe critical condition or other circumstances that make the study medically inadvisable
• • Unlikely to adhere to follow up visits during the study period (e.g. patients who live or work very far away) AND not reachable by phone for follow-up information
• • Pregnant or lactating woman